The JAK2 V617F Activating Tyrosine Kinase Mutation is an Infrequent Event in Both "atypical" Myeloproliferative Disorders and Myelodysplastic Syndromes

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2005 Apr 30

PMID 15860661

Citations 114

Authors

David P Steensma

Gordon W Dewald

Terra L Lasho

Heather L Powell

Rebecca F McClure

Ross L Levine

D Gary Gilliland

Ayalew Tefferi

Affiliations

Soon will be listed here.

Abstract

A somatic mutation in the JH2 autoinhibitory domain of the Janus kinase 2 (JAK2) tyrosine kinase was recently described in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. The prevalence of this mutation in either "atypical" myeloproliferative disorders (MPDs) or the myelodysplastic syndromes (MDSs) is unknown. Bone marrow-derived genomic DNA from 245 patients--119 with chronic myelomonocytic leukemia (CMML), 101 with MDS, 11 with hypereosinophilic syndrome (HES), 8 with systemic mastocytosis (SM), and 6 with chronic neutrophilic leukemia (CNL)--was screened for the JAK2 V617F mutation. A mutant allele was detected in 11 patients: 3 with CMML (3%), 5 with MDS (5%), 2 with SM, and 1 with CNL. Interestingly, one of the patients with SM and the patient with CNL with JAK2 V617F had a history of lymphoma, and this patient with SM also had associated myelofibrosis and CMML. The current observation strengthens the specific association between JAK2 V617F and classic MPD, but also suggests an infrequent occurrence in other myeloid disorders.

Citing Articles

How we diagnose Myelodysplastic syndromes.

Oster H, Mittelman M Front Oncol. 2024; 14:1415101.

PMID: 39346739 PMC: 11427428. DOI: 10.3389/fonc.2024.1415101.

Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms.

Gorantla S, Prince G, Osius J, Dinesh D, Boddu V, Duyster J Front Oncol. 2024; 14:1430833.

PMID: 39091915 PMC: 11291247. DOI: 10.3389/fonc.2024.1430833.

A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance.

Gorantla S, Mueller T, Albers-Leischner C, Rudelius M, von Bubnoff N, Duyster J Mol Oncol. 2023; 18(2):415-430.

PMID: 38104968 PMC: 10850816. DOI: 10.1002/1878-0261.13566.

Clonal haematopoiesis - a novel entity that modifies pathological processes in elderly.

Belotserkovskaya E, Golotin V, Uyanik B, Demidov O Cell Death Discov. 2023; 9(1):345.

PMID: 37726289 PMC: 10509183. DOI: 10.1038/s41420-023-01590-z.

Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review.

Fontana D, Elli E, Pagni F, Piazza R Cancers (Basel). 2023; 15(12).

PMID: 37370785 PMC: 10296742. DOI: 10.3390/cancers15123175.

References

Harris N, Jaffe E, Diebold J, Flandrin G, Muller-Hermelink H, Vardiman J . World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17(12):3835-49. DOI: 10.1200/JCO.1999.17.12.3835. View

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

Druker B, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344(14):1031-7. DOI: 10.1056/NEJM200104053441401. View

Nosslinger T, Reisner R, Gruner H, Tuchler H, Nowotny H, Pittermann E . Dysplastic versus proliferative CMML--a retrospective analysis of 91 patients from a single institution. Leuk Res. 2001; 25(9):741-7. DOI: 10.1016/s0145-2126(01)00014-5. View

Boultwood J, Wainscoat J . Clonality in the myelodysplastic syndromes. Int J Hematol. 2001; 73(4):411-415. DOI: 10.1007/BF02994002. View

Bueno J, Torrequebrada A, Lopez A, Vallespi T, Massague I . Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res. 2002; 26(9):821-4. DOI: 10.1016/s0145-2126(02)00021-8. View

Apperley J, Gardembas M, Melo J, Russell-Jones R, Bain B, Baxter E . Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002; 347(7):481-7. DOI: 10.1056/NEJMoa020150. View

Steensma D, Tefferi A . The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003; 27(2):95-120. DOI: 10.1016/s0145-2126(02)00098-x. View

Cortes J . CMML: a biologically distinct myeloproliferative disease. Curr Hematol Rep. 2003; 2(3):202-8. View

10.

Pardanani A, Elliott M, Reeder T, Li C, Baxter E, Cross N . Imatinib for systemic mast-cell disease. Lancet. 2003; 362(9383):535-6. DOI: 10.1016/s0140-6736(03)14115-3. View

11.

Onida F, Beran M . Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep. 2004; 3(3):218-26. View

12.

Sandberg E, Wallace T, Godeny M, VonDerLinden D, Sayeski P . Jak2 tyrosine kinase: a true jak of all trades?. Cell Biochem Biophys. 2004; 41(2):207-32. DOI: 10.1385/cbb:41:2:207. View

13.

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51(2):189-99. View

14.

Germing U, Gattermann N, Minning H, Heyll A, Aul C . Problems in the classification of CMML--dysplastic versus proliferative type. Leuk Res. 1998; 22(10):871-8. DOI: 10.1016/s0145-2126(97)00192-6. View

15.

Tefferi A . The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview. Mayo Clin Proc. 1998; 73(12):1177-84. DOI: 10.4065/73.12.1177. View

16.

Pardanani A, Brockman S, Paternoster S, Flynn H, Ketterling R, Lasho T . FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004; 104(10):3038-45. DOI: 10.1182/blood-2004-03-0787. View

17.

Steensma D, Gibbons R, Higgs D . Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood. 2004; 105(2):443-52. DOI: 10.1182/blood-2004-07-2792. View

18.

Elliott M, Hanson C, Dewald G, Smoley S, Lasho T, Tefferi A . WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2004; 19(2):313-7. DOI: 10.1038/sj.leu.2403562. View

19.

OHare T, Walters D, Deininger M, Druker B . AMN107: tightening the grip of imatinib. Cancer Cell. 2005; 7(2):117-9. DOI: 10.1016/j.ccr.2005.01.020. View

20.

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View